Title: |
Expert consensus on rational use of osteoporosis drugs (2023) |
Edition: |
Original |
Classification: |
Experts consensus |
Field: |
Treatment |
Countries and regions: |
China |
Guidelines users: |
Health care workers |
Evidence classification method: |
Oxford Centre for Evidence-Based Medicine: Levels of Evidence |
Development unit: |
Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association |
Registration time: |
2023-09-07 |
Registration number: |
PREPARE-2023CN679 |
Purpose of the guideline: |
To offer evidence-based and practical recommendations for the rational utilization of osteoporosis medications in clinical settings, with a focus on ensuring patient safety and optimizing treatment outcomes. |